How Workplace Safety Creates Repeat Demand for Ansell (ASX:ANN)

Aditi Sarkar

21 September 2026 08:38 PM AEST

How Workplace Safety Creates Repeat Demand for Ansell (ASX:ANN)

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

• Ansell makes protective gloves and clothing for industrial and healthcare use, consumable products that customers buy repeatedly.

• Sales rose to about US$2.14 billion in the 2026 financial year, with organic growth of 5.7% and a sharply higher.

• The integration of Kimberly-Clark's personal protective equipment Business has broadened Ansell's range and more than doubled that unit's profit contribution.

• That pattern of repeat demand, driven by the everyday requirements of workplace safety and hygiene, is the foundation of Ansell's.

Ansell (ASX: ANN) is a global maker of protective gloves and clothing and a member of the S&P/ASX 200. Although it is classified within the health care sector, its products span two broad markets: industrial workplaces, where workers need gloves and garments to protect against chemicals, cuts and other hazards, and healthcare settings, where surgical and examination gloves are essential. What links these markets is a simple, commercial feature - Ansell's products are consumables. They are used once, or for a short period, and then discarded, which means customers must buy them again and again.

That pattern of repeat demand, driven by the everyday requirements of workplace safety and hygiene, is the foundation of Ansell's business and the reason it can generate steady, recurring sales.

How workplace safety drives the business

Across factories, laboratories, hospitals, food-processing plants and construction sites, protective equipment is not optional. Regulations, workplace-safety standards and basic duty of care require employers to provide appropriate protection, and in healthcare, infection control demands single-use gloves in vast quantities. Because these products are consumed in use, they must be continually replenished, generating a stream of repeat orders that is far more stable than one-off equipment sales.

The 2026 result

For the year to 30 June 2026, Ansell reported sales of about US$2.14 billion, with organic constant-currency growth of 5.7%. Both of its main divisions performed well: Healthcare delivered Earnings before interest and tax of US$170.7 million, and Industrial delivered EBIT of US$170.6 million, leaving the two segments almost evenly balanced.

The Kimberly-Clark acquisition

A major development for Ansell has been its Acquisition of Kimberly-Clark's personal protective equipment business, which it has been integrating into its operations. The deal expanded Ansell's product range, particularly in scientific and cleanroom protective equipment, and added new customers and Manufacturing capability.

Two balanced divisions

Ansell's roughly even split between Healthcare and Industrial earnings gives it useful balance. The Healthcare division supplies surgical and examination gloves and related products to hospitals, clinics and laboratories, where Demand is driven by medical activity and infection-control requirements. The Industrial division supplies gloves and clothing that protect workers in manufacturing, chemicals, automotive, food and other industries against physical and chemical hazards.

The risks

Ansell faces several risks. Its markets are competitive, with numerous glove and protective-equipment manufacturers, and much of its output is produced in Asia, exposing it to manufacturing costs, raw-material prices - particularly for the rubber and synthetic materials used in gloves - and supply-chain disruption. Currency movements matter, as Ansell reports in US dollars while operating globally and listing in Australia.

A consumables business at its core

Despite these risks, Ansell's fundamental strength is clear. It sells essential protective products that workplaces and healthcare settings need continually and must repurchase, giving it a durable base of recurring demand. The 2026 result, with solid organic growth, balanced divisional earnings, a much higher Dividend and a strongly performing acquired business, reflected that strength in action.

What to watch next

Ansell reports half-yearly. The figures that matter most are total sales and organic growth, the EBIT of the Healthcare and Industrial divisions, adjusted earnings per share, and the dividend. Commentary on demand conditions in each market, on raw-material and manufacturing costs, and on pricing gives insight into the health of the business.

FAQs

Q: What is the main business focus of Ansell (ASX:ANN)?

A: Ansell (ASX: ANN) is a global maker of protective gloves and clothing and a member of the S&P/ASX 200. Although it is classified within the health care sector, its products span two broad markets: industrial workplaces, where workers need gloves and garments to protect against chemicals, cuts and other hazards, and healthcare settings, where surgical.

Q: Which 2026 figures are important for Ansell?

A: For the year to 30 June 2026, Ansell reported sales of about US$2.14 billion, with organic constant-currency growth of 5.7%. Both of its main divisions performed well: Healthcare delivered earnings before interest and tax of US$170.7 million, and Industrial delivered EBIT of US$170.6 million, leaving the two segments almost evenly balanced..

Q: What are the main risks to consider for Ansell?

A: Ansell faces several risks. Its markets are competitive, with numerous glove and protective-equipment manufacturers, and much of its output is produced in Asia, exposing it to manufacturing costs, raw-material prices - particularly for the rubber and synthetic materials used in gloves - and supply-chain disruption. Currency movements matter, as Ansell reports in US dollars while.

Q: What should investors watch next for Ansell?

A: Ansell reports half-yearly. The figures that matter most are total sales and organic growth, the EBIT of the Healthcare and Industrial divisions, adjusted earnings per share, and the dividend. Commentary on demand conditions in each market, on raw-material and manufacturing costs, and on pricing gives insight into the health of the business..

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.